OBJECTIVES: To compare the characteristics of younger and older subjects with diffuse cutaneous systemic sclerosis (SSc) entering clinical trials. METHODS: Subjects were participants in three randomised interventional trials that shared relative uniformity of demographics and disease characteristics. Only subjects with diffuse cutaneous systemic sclerosis were evaluated. To maximise possible differences, the lowest (age<38 years) and highest quartiles (age>53 years) were used, and a total of 264 diffuse cutaneous SSc (dcSSc) subjects were identified. For the comparison between the two age groups, generalised linear mixed or linear models with adjustment for population norms, demographics and medications were employed to assess differences attributable to subject age. RESULTS: After adjustment for population norms and study effects, differences in diastolic blood pressure, alkaline phosphatase, AST, and creatinine phosphokinase (CK) were found between the two age groups. After further adjustment for demographics, disease duration and medications, older SSc patients still had significantly higher alkaline phosphatase (11 U/L higher), and lower CK (76 U/L lower) than younger patients (p<0.003 for all). All other variables were not significantly different in the two age groups. CONCLUSIONS: Clinical baseline differences exist between younger and older patients with SSc. However, after adjustment for population norms and potential confounders, including medications, only differences in alkaline phosphatise (only 11U/L) and CK (76 U/L) remain. Overall, older patients with SSc in clinical trials seem to be more similar to younger patients than was previously thought.
RCT Entities:
OBJECTIVES: To compare the characteristics of younger and older subjects with diffuse cutaneous systemic sclerosis (SSc) entering clinical trials. METHODS: Subjects were participants in three randomised interventional trials that shared relative uniformity of demographics and disease characteristics. Only subjects with diffuse cutaneous systemic sclerosis were evaluated. To maximise possible differences, the lowest (age<38 years) and highest quartiles (age>53 years) were used, and a total of 264 diffuse cutaneous SSc (dcSSc) subjects were identified. For the comparison between the two age groups, generalised linear mixed or linear models with adjustment for population norms, demographics and medications were employed to assess differences attributable to subject age. RESULTS: After adjustment for population norms and study effects, differences in diastolic blood pressure, alkaline phosphatase, AST, and creatinine phosphokinase (CK) were found between the two age groups. After further adjustment for demographics, disease duration and medications, older SSc patients still had significantly higher alkaline phosphatase (11 U/L higher), and lower CK (76 U/L lower) than younger patients (p<0.003 for all). All other variables were not significantly different in the two age groups. CONCLUSIONS: Clinical baseline differences exist between younger and older patients with SSc. However, after adjustment for population norms and potential confounders, including medications, only differences in alkaline phosphatise (only 11U/L) and CK (76 U/L) remain. Overall, older patients with SSc in clinical trials seem to be more similar to younger patients than was previously thought.
Authors: Arnold E Postlethwaite; Weng Kee Wong; Philip Clements; Soumya Chatterjee; Barri J Fessler; Andrew H Kang; Joseph Korn; Maureen Mayes; Peter A Merkel; Jerry A Molitor; Larry Moreland; Naomi Rothfield; Robert W Simms; Edwin A Smith; Robert Spiera; Virginia Steen; Kenneth Warrington; Barbara White; Frederick Wigley; Daniel E Furst Journal: Arthritis Rheum Date: 2008-06
Authors: J E Pope; N Bellamy; J R Seibold; M Baron; M Ellman; S Carette; C D Smith; I M Chalmers; P Hong; D O'Hanlon; E Kaminska; J Markland; J Sibley; L Catoggio; D E Furst Journal: Arthritis Rheum Date: 2001-06
Authors: U A Walker; A Tyndall; L Czirják; C Denton; D Farge-Bancel; O Kowal-Bielecka; U Müller-Ladner; C Bocelli-Tyndall; M Matucci-Cerinic Journal: Ann Rheum Dis Date: 2007-01-18 Impact factor: 19.103
Authors: Kenneth Scalapino; Thaschawee Arkachaisri; Mary Lucas; Noreen Fertig; David J Helfrich; Aldo V Londino; Virginia D Steen; Thomas A Medsger Journal: J Rheumatol Date: 2006-04-01 Impact factor: 4.666
Authors: Dinesh Khanna; Philip J Clements; Daniel E Furst; Joseph H Korn; Michael Ellman; Naomi Rothfield; Fredrick M Wigley; Larry W Moreland; Richard Silver; Youn H Kim; Virginia D Steen; Gary S Firestein; Arthur F Kavanaugh; Michael Weisman; Maureen D Mayes; David Collier; Mary E Csuka; Robert Simms; Peter A Merkel; Thomas A Medsger; Martin E Sanders; Paul Maranian; James R Seibold Journal: Arthritis Rheum Date: 2009-04
Authors: Maureen D Mayes; James V Lacey; Jennifer Beebe-Dimmer; Brenda W Gillespie; Brenda Cooper; Timothy J Laing; David Schottenfeld Journal: Arthritis Rheum Date: 2003-08
Authors: Lorinda Chung; Harrison W Farber; Raymond Benza; Dave P Miller; Lori Parsons; Paul M Hassoun; Michael McGoon; Mark R Nicolls; Roham T Zamanian Journal: Chest Date: 2014-12 Impact factor: 9.410
Authors: Marco A Alba; César Velasco; Carmen Pilar Simeón; Vicent Fonollosa; Luis Trapiella; María Victoria Egurbide; Luis Sáez; María Jesús Castillo; José Luis Callejas; María Teresa Camps; Carles Tolosa; Juan José Ríos; Mayka Freire; José Antonio Vargas; Gerard Espinosa Journal: Medicine (Baltimore) Date: 2014-03 Impact factor: 1.889